eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (0.00%) As of 08/29/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EFTR vs. AMPE, PXMD, CALA, CLVR, ONCSQ, ATNFW, LBPSW, AEHAW, AIMDW, and ALVOWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Ampio Pharmaceuticals (AMPE), PaxMedica (PXMD), Calithera Biosciences (CALA), Clever Leaves (CLVR), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), and Alvotech (ALVOW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Its Competitors Ampio Pharmaceuticals PaxMedica Calithera Biosciences Clever Leaves OncoSec Medical 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Ampio Pharmaceuticals (NYSE:AMPE) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings. Is AMPE or EFTR more profitable? Company Net Margins Return on Equity Return on Assets Ampio PharmaceuticalsN/A N/A N/A eFFECTOR Therapeutics N/A N/A N/A Do insiders & institutionals hold more shares of AMPE or EFTR? 5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, AMPE or EFTR? Ampio Pharmaceuticals has a beta of 4.69, suggesting that its stock price is 369% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Does the media favor AMPE or EFTR? In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score. Company Overall Sentiment Ampio Pharmaceuticals Neutral eFFECTOR Therapeutics Neutral Which has higher earnings & valuation, AMPE or EFTR? Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmpio PharmaceuticalsN/AN/A-$8.63M-$11.010.00eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.080.00 SummaryAmpio Pharmaceuticals and eFFECTOR Therapeutics tied by winning 3 of the 6 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EFTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$829.26M$5.66B$9.84BDividend YieldN/A4.84%3.93%4.04%P/E Ratio0.001.1283.2726.61Price / SalesN/A120.95451.26176.28Price / CashN/A19.5637.7059.65Price / Book0.006.6110.556.59Net Income-$35.81M-$5.06M$3.27B$266.12M7 Day PerformanceN/A0.71%0.42%0.16%1 Month PerformanceN/A5.31%5.91%3.01%1 Year PerformanceN/A18.37%48.11%19.65% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.4%$1KN/A0.0010AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020PXMDPaxMedicaN/A$0.00flatN/A-99.9%$2KN/A0.002CALACalithera Biosciences0.5177 of 5 stars$0.00flatN/A-98.0%$1KN/A0.0060CLVRClever LeavesN/A$0.00flatN/A+0.0%$1K$17.42M0.00560ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040ATNFW180 Life SciencesN/A$0.27+24.8%N/A+2,288.0%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.24-40.2%N/A+242.9%$0.00$110.87K0.0040Positive NewsGap UpALVOWAlvotechN/A$1.23+5.3%N/A-57.7%$0.00$560.10M0.004Positive NewsGap Down Related Companies and Tools Related Companies Ampio Pharmaceuticals Alternatives PaxMedica Alternatives Calithera Biosciences Alternatives Clever Leaves Alternatives OncoSec Medical Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EFTR Stock Alerts